Table 1.
Selected ongoing studies of targeted therapy for extensive stage small-cell lung cancer
| Therapy | Molecular target | Study name | Study phase | ClinicalTrials.gov study identifier | Estimated primary completion date |
|---|---|---|---|---|---|
| First line | |||||
| Veliparib (plus carboplatin and etoposide) | PARP | M14-361/2014-001764-35 | I/II | NCT02289690 | August 2017 |
| Rova-T (± cisplatin and etoposide) | DLL3 | SCRX001-004 | I | NCT02819999 | October 2020 |
| Maintenance | |||||
| Olaparib plus cediranib or no maintenance treatment (after cis/carboplatin and etoposide ± cediranib) | PARP; VEGF-RTKs | SUKSES-B | II | NCT02899728 | December 2018 |
| Rova-T plus dexamethasone versus placebo (after cis/carboplatin and etoposide) | DLL3 | MERU | III | NCT03033511 | August 2019 |
| Second line and beyond | |||||
| Olaparib plus CRLX101 (nanoparticle camptothecin) | PARP | 160107/16-C-0107 | I/II | NCT02769962 | June 2018 |
| Olaparib plus cediranib | PARP; VEGF-RTKs | NCI-2015-01097/9881 | II | NCT02498613 | May 2018 |
| Olaparib plus durvalumab | PARP; PD-L1 | MEDIOLA | I/II | NCT02734004 | October 2018 |
| Olaparib plus AZD1775 | PARP; WEE1 | D6010C00005/REFMAL 384 | I | NCT02511795 | January 2018 |
| AZD1775 | WEE1 | 2015-10-178 | II | NCT02593019 | March 2017 |
| AZD1775 plus carboplatin | WEE1 | D419QC00002/2016-001202-42 | II | NCT02937818 | May 2020 |
| Rova-T | DLL3 | TRINITY | II | NCT02674568 | March 2017 |
| Rova-T | DLL3 | SCRX001-007 | I | NCT02874664 | June 2017 |
Cis/carboplatin, cisplatin or carboplatin; DLL3, Delta-like protein 3; PARP, poly [ADP-ribose] polymerase; PD-L1, programmed cell death 1 ligand 1; Rova-T, rovalpituzumab tesirine; VEGF-RTKs, vascular endothelial growth factor receptor tyrosine kinases; WEE1, Wee1-like protein kinase.